The Safety of the Blood Supply

Slides:



Advertisements
Similar presentations
FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.
Advertisements

Blood Donor Written Statement of Understanding
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
Development of Guidance Documents Jennifer Scharpf, M. P. H
Unit 1 Part 1 Blood Collection
The need is constant. The gratification is instant. Give blood. TM Blood Basics.
Susan N. Hocevar, MD Medical Officer Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality and Promotion Investigation Framework.
CBER 1 Normal Source Plasma Donor Program Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
Transfusion Transmission of HIV 1. Past & Current Risk Estimates of Transfusion-Transmitted HIV Infection 2. Layers of Safety in Protection of the Blood.
Chapter 22 Regulatory & Advisory Agencies Copyright 2003, Elsevier Science (USA). All rights reserved. No part of this product may be reproduced or transmitted.
Americas Technical Advisory Group ICCBBA ISBT 128 Blood Product Labeling – A Hospital Perspective Americas Technical Advisory Group ICCBBA.
F. Kourgia, M. Vini, E. Zervou
FDA Basics: Tissue Safety
Why "We" should Care Presented to: International Blood Safety Forum Jed Gorlin MD, MBA March 20, 2015 ©2015 Innovative Blood Resources, Proprietary & Confidential.
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
Donor Screening & Blood Collection. Donor Screening All blood comes from VOLUNTEER donors. Screening performed to ensure donor is healthy. Starts with.
Donor Selection Criteria Dr. Mindy Goldman Transfusion Medicine Residents May 24, 2011.
Risks and Indications for RBCs Transfusions David Stroncek, MD Chief, Laboratory Services Section Department of Transfusion Medicine, Clinical Center,
Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM.
Lookback study for transfusion- related HBV infection in Japan Tokyo Metropolitan Red Cross Blood Center Masahiro Satake.
European Health Forum 2003Reinhart Waneck1 Safety and Quality of Human Blood Products and Human Blood Derivatives in an Enlarged European Union The experience.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
FDA and American Red Cross Blood Supply Safety & Protection Geoff Withnell, CQE, CQA, CQMgr System Design Engineer American Red Cross.
+ Dr. Megan Rowley Consultant in Transfusion Medicine Blood Transfusion.
TRANSFUSION SAFETY AN INTERNATIONAL FLAVOR. RISK DATA – U.S. Motor cycling 1:50 20 Cigarettes/d 1:200 Hit by car 1:20,000 BC pills 1:50,000 Earthquake.
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
Ensuring Product Quality in Gene Transfer Clinical Trials
Click to edit Master title style Click to edit Master subtitle style February Regulatory framework for blood and blood components Transfusion Medicine.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Regulation of Blood & Blood Products and Cell, Tissue & Gene Therapies Elizabeth Read, MD Epi 260 UCSF May 9, 2012.
CBER 1 Establishment Submissions Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
CBER Red Blood Cell Immunization Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia.
The Journey of Blood. Blood- the life source Slide 1: Blood is a scarce and vital national resource which cannot be synthesized. About 80 million unit.
 What is blood?  Use of donated blood products  Who can donate? Volunteers Only  Questions about eligibility  Blood types  Blood safety  Baby blood.
Revision Process for the PHS Guideline for Reducing HIV, HBV and HCV Transmission through Solid Organ Transplantation Matthew J. Kuehnert, M.D. Office.
Apheresis Blood Components
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
COMPLIANCE ACTIONS FDA Regulation & Licensure of Whole Blood & Blood Components, Including Source Plasma September 15-16, 2009 Helen Cowley Office of Compliance.
Blood Basics. Blood. What is it? There are four main components of blood. Red Blood Cells White Blood Cells Platelets Plasma.
REGULATIONS FOR BLOOD and BLOOD PRODUCTS JILL HOAG BS, SBB(ASCP) CQA(ASQ) AABB STAFF LEAD ASSESSOR 1.
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
CBER Alternative Procedures “Variances” Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 15, 2009.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
12 th Annual FDA & the Changing Paradigm for Blood Regulation – 01/16/2009 – Las Vegas, NV – Gilliam B. Conley 1 FDA perspective on “Where are we? Where.
Hello. Donor Selection Conditions of Donation Register of Individual & History Age Weight Temperature Pulse Blood Pressure Minimum Hb.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.
Saftey Agencies in Healthcare Practice OSHA CDCP CLIA FDA ISO WHO NIH USDHHS.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.
Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,
Surface of blood cells have antigens on them Surface of blood cells have antigens on them Plasma includes antibodies Plasma includes antibodies Antibodies.
Allogeneic donor selection and blood collection by Mohammed Abu-basha 1.
Transfusion Related Acute Lung Injury (TRALI)
Confidential Unit Exclusion Donors may be given the opportunity to indicate confidentially whether their blood is or is not suitable for transfusion to.
Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Ann Intern Med. 2012;157(1): doi: / Figure Legend:
Presented by Karen Dosanjh Quality Director Blood Systems
Presentation transcript:

The Safety of the Blood Supply Richard J. Davey, MD Director, Division of Blood Applications, OBRR, CBER, FDA

Blood Donation in the United States Eight million plus volunteers First-time donors 15-25% Average 1.6 donations per year 15 M units of whole blood collected 4% autologous 2% directed 14 M units of RBCs transfused % who can donate. 40 - 45% % who actually donate. 2.5 - 4.5% Periodic shortages and appeals. Postponement of surgery.

Blood Organization in the USA AABB. 2400 institutions. 9000 members. Transfusion. Standards. Annual meeting. American Red Cross. 45% of blood supply. 35 blood centers. One FDA license. America’s Blood Centers. 45% of blood supply. 70 blood centers. Separate FDA licenses. Hospital blood banks. 10% of blood supply. FDA registered.

Regulation of the US Blood Supply FDA insures the “safety, purity and potency” of blood products. Blood is subject to both “biologics” and “drug” regulatory oversight. cGMP: “Current Good Manufacturing Practices” Code of Federal Regulations (CFR) FDA Guidances FDA Registration. Local collection and testing of blood, or transfusing blood only (hospitals) FDA License: Collection, testing and shipping across state lines. (blood centers) FDA enforcement options: “483” observations, warning letters, suspension, revocation. State regulations, OSHA, CDC, AABB and CAP

Five Layers of Safety Selection of suitable donors Donor history questionnaire Limited physical examination Donor deferral registries Testing for infectious agents Quarantining of blood while verifying suitability Taking corrective actions to address errors

Blood Donor Qualification Regulations and guidances Hemoglobin levels Risk behavior questions Travel Malaria vCJD (“mad cow disease”) Testing HIV, HCV, HBV, others Chagas disease Dengue ? XMRV ?

Transfusion Transmitted Disease Post –Transfusion Hepatitis Risk: 1969-2005 Volunteer Donors HBsAg HTLV 1.0 HTLV-I/II HCV 1.0 HIV-1 HCV/HIV NAT ALT HIV-1/2 HCV 2.0 WNV NAT HBsAg 3 CUE Anti-HBc HCV 3.0 p24 Ag HTLV 2.0 Chagas? Babesiosis? vCJD? After H. Alter

Hospital Transfusion Issues: Events Reported by the SHOT Program in England, 1996-2001. Incorrect blood transfused Acute reaction Delayed reaction PTP TRALI Infections GVHD

Transfusion Safety Options Hand-held bar code scanners Radio frequency “smart-tags” and readers (RFID) Wi-Fi technology Blood bag “dispenser” systems Dedicated phlebotomists Two separate blood samples on all new patients Transfusion Safety Officer

Transfusion Safety Officer Most serious hazards of transfusion occur outside of the laboratory The principal role of the TSO is to work outside of the laboratory to improve patient safety during transfusions Most TSOs are RNs or PAs with >3 yrs experience, preferably in med-surg in-patient settings

Blood Safety Innovations

Research: Is “Old” Blood OK?

Future Directions in Transfusion Science Understand blood storage lesion Better storage containers and conditions Blood management Appropriate use of blood to minimize its use Pathogen reduction technologies Minimize infectious hazards Artificial oxygen carriers Minimize reactions, storage lesion and infectious hazards

The Primary Focus of Blood Safety: The Patient FDA Safe Donors Hospitals The Patient Industry Research Blood Centers

Questions about today's webinar? Toll-free 1-888-INFO-FDA (888-463-6332) One the web www.fda.gov E-mail ocod@fda.hhs.gov